A Democratic bill with 4 Republican cosponsors · See all 7 cosponsors
Last activity — Committee on Health, Education, Labor, and Pensions. Hearings held.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
The MAPS Act aims to improve how the Federal government identifies and handles health and national security risks regarding medicine. The bill requires the Secretary of Health and Human Services to maintain an "Essential Medicines List" that includes drugs critical for medical priority, chronic conditions, or military preparedness. It mandates a comprehensive risk assessment of the supply chains for these medicines to identify vulnerabilities. Additionally, the Act directs the creation of a system to map pharmaceutical supply chains using data analytics. The Secretary of Defense is also required to report on drugs purchased by the Department of Defense that involve sourcing or manufacturing in the People's Republic of China.
Yes· 3 of 6
- Scored +5
Does this make the country readier for the next outbreak?
The bill enhances preparedness by identifying essential medicines and their supply chain vulnerabilities.
- Scored +5
Does this better protect the country from computer attacks?
The bill requires assessments of cybersecurity threats to pharmaceutical supply chains.
- Scored +4
Does this make health care easier to get in general?
By mapping and mitigating supply chain risks, the bill helps ensure continuous access to essential medicines.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Protection against shortages: The creation of an Essential Medicines List includes drugs of "greatest priority for providing health care" and those "at high risk of shortage," which helps address needs for patients with chronic conditions (Section 2(a)).
-
Improved national security: The bill mandates a risk assessment to identify "public health and national security risks, including cybersecurity threats" related to drug supply chains (Section 3(b)(5)).
-
Mitigation of supply chain risks: The Secretary is tasked with determining how the Federal Government will mitigate national security risks, including through the use of "authorities under the Defense Production Act of 1950" (Section 3(b)(7)).
-
Enhanced supply chain visibility: The Act seeks to "map, or otherwise visualize, the supply chains" from raw materials to finished drugs, which can help identify vulnerabilities (Section 4(a)(1)).
Potential Negative Impacts for People
- No specific negative impacts are explicitly stated in the text regarding burdens on individuals or groups.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Healthcare
- Does this make the country readier for the next outbreak? — The bill enhances preparedness by identifying essential medicines and their supply chain vulnerabilities. Does this make health care easier to get in general? — By mapping and mitigating supply chain risks, the bill helps ensure continuous access to essential medicines.
- Governance And Ideology
- Does this make what the government does easier for the public to see? — The bill requires regular reporting and public publication of the Essential Medicines List and risk assessment findings. Does this give the federal government more power? — The bill expands federal oversight and data-gathering requirements regarding pharmaceutical supply chains.
- National Security And Foreign Policy
- Does this better protect the country from computer attacks? — The bill requires assessments of cybersecurity threats to pharmaceutical supply chains.
- Economy And Finance
- Does this give people more protection from unfair business practices? — The bill improves consumer protection by identifying and mitigating risks of essential drug shortages.
- 3/19/2026
- Committee on Health, Education, Labor, and Pensions. Hearings held.
- 11/7/2025
- 1 Cosponsor added.
- 5/15/2025
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 6 Cosponsors added.
- Introduced in Senate
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Tom CottonRepublican · Arkansas
Joni ErnstRepublican · Iowa
Angus KingIndependent · Maine
Timothy KaineDemocrat · Virginia
James LankfordRepublican · Oklahoma
Elissa SlotkinDemocrat · Michigan
Rick ScottRepublican · Florida